{"id":13381,"date":"2020-12-14T13:10:00","date_gmt":"2020-12-14T12:10:00","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=13381"},"modified":"2025-02-26T15:40:15","modified_gmt":"2025-02-26T14:40:15","slug":"edito-jouvin-marche-14-12-2020","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/","title":{"rendered":"\u00c9dito par \u00c9velyne Jouvin-Marche"},"content":{"rendered":"\n<p>En ce mois de mars 2020, la plan\u00e8te faisait face \u00e0 la mont\u00e9e en puissance d\u2019une crise sanitaire sans pr\u00e9c\u00e9dent due aux cons\u00e9quences de l\u2019\u00e9mergence d\u2019un nouveau virus : le SARS-CoV2\u2026 C\u2019est au m\u00eame moment que nous avons lanc\u00e9 le chantier de r\u00e9alisation du site web <strong>Interface nationale ANTIBIOR\u00c9SISTANCE<\/strong>. D\u2019un c\u00f4t\u00e9, contre ce virus responsable de la pand\u00e9mie que nous subissons, nous n\u2019avons pas \u00e0 ce jour de traitement. D\u2019un autre, pour combattre la plupart des bact\u00e9ries, nous avons les antibiotiques. Pourtant, l\u2019Organisation mondiale de la sant\u00e9 rapporte que 700 000 personnes meurent chaque ann\u00e9e \u00e0 cause de bact\u00e9ries r\u00e9sistantes aux traitements. Si rien n\u2019est fait d\u2019ici \u00e0 2050, elles pourraient faire 10 millions de victimes par an\u2026 Virus, bact\u00e9ries r\u00e9sistantes, il appara\u00eet par le nombre de victimes qu\u2019ils font les uns comme les autres, tout aussi urgent d\u2019agir, et un constat s\u2019impose : la lutte contre l\u2019antibior\u00e9sistance est tout autant, voire plus que jamais, d\u2019actualit\u00e9.<\/p>\n\n\n\n<p>Pour \u00e9laborer l\u2019Interface nationale antibior\u00e9sistance, m\u2019ont rejointe, en plein \u00ab confinement \u00bb \u2013 chacun chez soi, certes, mais toujours ensemble \u2013 du c\u00f4t\u00e9 Inserm :<\/p>\n\n\n\n<ul>\n<li>Guia Carrara et Erica Telford, mes coll\u00e8gues de l\u2019<a href=\"https:\/\/i3m.aviesan.fr\/\" target=\"_blank\" rel=\"noopener noreferrer\">ITMO I3M<\/a><\/li>\n\n\n\n<li>Myriem Belkacem du d\u00e9partement Communication dirig\u00e9 par Carine Delrieu<\/li>\n\n\n\n<li>Taher Benromdhane et Djamel Bahamid du Syst\u00e8me d\u2019information dirig\u00e9 par Sammy Sahnoune<\/li>\n<\/ul>\n\n\n\n<p>C\u00f4t\u00e9 prestation externe, nous avons pu compter sur la comp\u00e9tence, bien s\u00fbr, mais aussi sur la grande implication de l\u2019\u00e9quipe de l\u2019agence<a href=\"http:\/\/www.mlcom.fr\" target=\"_blank\" rel=\"noopener noreferrer\"> ML Com<\/a>&nbsp;:<\/p>\n\n\n\n<ul>\n<li>Emmanuel Auchet, Eric Blanc et Gloria Fernandes, sous la conduite de son directeur Christian Ferreira.<\/li>\n<\/ul>\n\n\n\n<p>Depuis novembre, l\u2019\u00e9quipe a \u00e9t\u00e9 renforc\u00e9e par l\u2019arriv\u00e9e, au sein de l<a href=\"https:\/\/i3m.aviesan.fr\/\" target=\"_blank\" rel=\"noopener noreferrer\">\u2019ITMO I3M<\/a>, d\u2019Emilie Noguez, Charg\u00e9e de mission.<\/p>\n\n\n\n<p>Pour contrer les bact\u00e9ries et leurs r\u00e9sistances qui n\u2019ont pas de fronti\u00e8res, quelle riposte serait mieux appropri\u00e9e que de r\u00e9unir et de mobiliser des forces et des comp\u00e9tences venant d\u2019horizons vari\u00e9s ? C\u2019est dans cette dynamique qu\u2019a \u00e9t\u00e9 con\u00e7u et r\u00e9alis\u00e9 le site web Interface nationale ANTIBIOR\u00c9SISTANCE afin d\u2019offrir \u00e0 chacun des acteurs engag\u00e9s dans la lutte contre l\u2019antibior\u00e9sistance les multiples ressources n\u00e9cessaires pour mener \u00e0 bien ce combat : un r\u00e9pertoire de chercheurs et de professionnels de sant\u00e9, une visibilit\u00e9 des recherches et informations scientifiques issues du secteur acad\u00e9mique ou priv\u00e9 \u2013 industriels et startups \u2013, des syndicats des industries de sant\u00e9 ou encore de celui des essais cliniques.<\/p>\n\n\n\n<p>Les objectifs \u00e9nonc\u00e9s dans la feuille de route nationale de ma\u00eetrise de l\u2019antibior\u00e9sistance et du Comit\u00e9 strat\u00e9gique de fili\u00e8re industries et technologies de sant\u00e9 sur l\u2019antibior\u00e9sistance concernaient notamment la mise en place d\u2019une <strong>cartographie des forces fran\u00e7aises<\/strong> et d\u2019un <strong>portail regroupant des informations sur l\u2019antibior\u00e9sistance<\/strong>.<\/p>\n\n\n\n<p>Porte d\u2019entr\u00e9e, commune, intersectorielle et interactive, prenant en compte l\u2019approche \u00ab une seule sant\u00e9 \u00bb, l\u2019Interface nationale ANTIBIOR\u00c9SISTANCE, est pour VOUS :<\/p>\n\n\n\n<ul>\n<li>une <strong>base de donn\u00e9es nationale<\/strong> avec les principaux acteurs de l&#8217;antibior\u00e9sistance en France : chercheurs, CNR, biotechs, industriels, institutionnels, CIC en infectiologie<\/li>\n\n\n\n<li>une rubrique <strong>\u00ab Veille scientifique \u00bb\u00a0<\/strong>qui r\u00e9pertorie les publications fran\u00e7aises et internationales consacr\u00e9es \u00e0 l&#8217;antibior\u00e9sistance,<\/li>\n\n\n\n<li>une sous rubrique <strong>\u00ab\u00a0Les th\u00e9matiques de recherche en un clin d&#8217;\u0153il\u00a0\u00bb,<\/strong> donne acc\u00e8s \u00e0 une analyse bibliom\u00e9trique automatis\u00e9e des donn\u00e9es issues du <em>Web of Science<\/em> sur l\u2019ensemble des \u00e9quipes fran\u00e7aises<\/li>\n\n\n\n<li>une page <strong>\u00ab\u00a0Actualit\u00e9s\u00a0\u00bb<\/strong> regroupe les annonces des colloques, webinaires et appels \u00e0 projets interdisciplinaires en lien avec le domaine<\/li>\n\n\n\n<li>un onglet qui pr\u00e9sente les <strong>tutelles et partenaires<\/strong> du site<\/li>\n\n\n\n<li>une vision compl\u00e8te du <strong>Programme prioritaire de recherche (PPR) ANTIBIOR\u00c9SISTANCE.<\/strong><\/li>\n<\/ul>\n\n\n\n<p>Enfin, prochainement, les <strong>offres d&#8217;emplois et de missions <\/strong>relatives au domaine seront \u00e9galement accessibles en ligne. Une traduction du site web en anglais est programm\u00e9e pour 2021.<\/p>\n\n\n\n<p>Les premi\u00e8res \u00ab briques \u00bb de cette interface \u00e9tant pos\u00e9es, nous esp\u00e9rons que vous serez tr\u00e8s nombreux \u00e0 rejoindre notre d\u00e9marche. En effet, ce nouvel outil de communication est le v\u00f4tre et il ne peut \u00e9voluer et continuer \u00e0 se construire que gr\u00e2ce \u00e0 vos contributions et diffusions du savoir et des connaissances acquises pour ma\u00eetriser cette nouvelle discipline \u2013l\u2019antibior\u00e9sistance\u2013 qui s\u2019est invit\u00e9e dans notre monde moderne.<\/p>\n\n\n\n<p>Juste un dernier mot pour dire tout simplement <strong>\u00ab&nbsp;MERCI&nbsp;\u00bb<\/strong> \u00e0 tous ceux qui ont collabor\u00e9 \u00e0 la construction de ce site dans une p\u00e9riode tr\u00e8s bouscul\u00e9e o\u00f9, curieusement, nous avons appris \u00e0 travailler diff\u00e9remment tout en pr\u00e9servant des valeurs partag\u00e9es telles que s\u00e9r\u00e9nit\u00e9, rigueur, \u00e9coute et dialogue constants. <strong>Un grand merci \u00e9galement<\/strong> \u00e0 la direction de l\u2019Inserm, Claire Giry, directrice g\u00e9n\u00e9rale d\u00e9l\u00e9gu\u00e9e et Gilles Bloch, pr\u00e9sident-directeur g\u00e9n\u00e9ral, et au directeur de l\u2019<a href=\"https:\/\/i3m.aviesan.fr\/\" target=\"_blank\" rel=\"noopener noreferrer\">ITMO I3M<\/a>, Yazdan Yazdanpanah pour m\u2019avoir accord\u00e9 toute leur confiance.<\/p>\n\n\n\n<p class=\"has-text-align-right\"><em>Publi\u00e9 le 14 d\u00e9cembre 2020<\/em><\/p>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\">Autrice<\/h3>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\"><figure class=\"wp-block-media-text__media\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"681\" src=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/12\/PortraitEvelyneJouvinMarche-1024x681.jpg\" alt=\"\" class=\"wp-image-6345 size-full\" srcset=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/12\/PortraitEvelyneJouvinMarche-1024x681.jpg 1024w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/12\/PortraitEvelyneJouvinMarche-300x200.jpg 300w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/12\/PortraitEvelyneJouvinMarche-768x511.jpg 768w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/12\/PortraitEvelyneJouvinMarche-1536x1022.jpg 1536w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/12\/PortraitEvelyneJouvinMarche-2048x1363.jpg 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><div class=\"wp-block-media-text__content\">\n<p><strong><strong>\u00c9velyne Jouvin-Marche<\/strong><\/strong><\/p>\n\n\n\n<p><em>Directeur de recherche Inserm,<br>directrice adjointe de l\u2019ITMO I3M,<br>coordinatrice du Programme prioritaire de recherche Antibior\u00e9sistance<\/em><\/p>\n<\/div><\/div>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>En ce mois de mars 2020, la plan\u00e8te faisait face \u00e0 la mont\u00e9e en puissance d\u2019une crise sanitaire sans pr\u00e9c\u00e9dent due aux cons\u00e9quences de l\u2019\u00e9mergence d\u2019un nouveau virus : le SARS-CoV2\u2026 C\u2019est au m\u00eame moment que nous avons lanc\u00e9 le chantier de r\u00e9alisation du site web Interface nationale ANTIBIOR\u00c9SISTANCE. D\u2019un c\u00f4t\u00e9, contre ce virus responsable [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":30164,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[3341],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u00c9dito par \u00c9velyne Jouvin-Marche - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00c9dito par \u00c9velyne Jouvin-Marche - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-14T12:10:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-26T14:40:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Portrait-EvelyneJouvinMarche-scaled-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1703\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Emmanuel Auchet\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Emmanuel Auchet\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/\"},\"author\":{\"name\":\"Emmanuel Auchet\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/dddace6035f5329dbab637f17f7a1ff8\"},\"headline\":\"\u00c9dito par \u00c9velyne Jouvin-Marche\",\"datePublished\":\"2020-12-14T12:10:00+00:00\",\"dateModified\":\"2025-02-26T14:40:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/\"},\"wordCount\":866,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Portrait-EvelyneJouvinMarche-scaled-1.jpg\",\"articleSection\":[\"Editoriaux\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/\",\"name\":\"\u00c9dito par \u00c9velyne Jouvin-Marche - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Portrait-EvelyneJouvinMarche-scaled-1.jpg\",\"datePublished\":\"2020-12-14T12:10:00+00:00\",\"dateModified\":\"2025-02-26T14:40:15+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Portrait-EvelyneJouvinMarche-scaled-1.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Portrait-EvelyneJouvinMarche-scaled-1.jpg\",\"width\":2560,\"height\":1703},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Editoriaux\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"\u00c9dito par \u00c9velyne Jouvin-Marche\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/dddace6035f5329dbab637f17f7a1ff8\",\"name\":\"Emmanuel Auchet\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u00c9dito par \u00c9velyne Jouvin-Marche - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/","og_locale":"fr_FR","og_type":"article","og_title":"\u00c9dito par \u00c9velyne Jouvin-Marche - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2020-12-14T12:10:00+00:00","article_modified_time":"2025-02-26T14:40:15+00:00","og_image":[{"width":2560,"height":1703,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Portrait-EvelyneJouvinMarche-scaled-1.jpg","type":"image\/jpeg"}],"author":"Emmanuel Auchet","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Emmanuel Auchet","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/"},"author":{"name":"Emmanuel Auchet","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/dddace6035f5329dbab637f17f7a1ff8"},"headline":"\u00c9dito par \u00c9velyne Jouvin-Marche","datePublished":"2020-12-14T12:10:00+00:00","dateModified":"2025-02-26T14:40:15+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/"},"wordCount":866,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Portrait-EvelyneJouvinMarche-scaled-1.jpg","articleSection":["Editoriaux"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/","name":"\u00c9dito par \u00c9velyne Jouvin-Marche - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Portrait-EvelyneJouvinMarche-scaled-1.jpg","datePublished":"2020-12-14T12:10:00+00:00","dateModified":"2025-02-26T14:40:15+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Portrait-EvelyneJouvinMarche-scaled-1.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Portrait-EvelyneJouvinMarche-scaled-1.jpg","width":2560,"height":1703},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/edito-jouvin-marche-14-12-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Editoriaux","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/"},{"@type":"ListItem","position":3,"name":"\u00c9dito par \u00c9velyne Jouvin-Marche"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/dddace6035f5329dbab637f17f7a1ff8","name":"Emmanuel Auchet"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-26 08:33:11","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/13381"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=13381"}],"version-history":[{"count":7,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/13381\/revisions"}],"predecessor-version":[{"id":30166,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/13381\/revisions\/30166"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/30164"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=13381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=13381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=13381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}